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Abstract
It is well defined that subpopulations of motoneurons have different vulnerability to
the pathology causing amyotrophic lateral sclerosis (ALS). In the spinal cord, the fast
fatigable motoneurons have been shown to be the first to degenerate, followed by
fatigue-resistant and slow motoneurons. In contrast motoneurons located in the Onuf’s
and oculomotor nuclei  appear to be resistant to disease.  With a focus on research
mainly  done  on  mice  overexpressing  the  mutated  human  superoxide  dismutase
(SOD1) protein, we review recent studies exploring the mechanisms that underlie the
selective vulnerability of the various motoneuron subtypes. By comparing differen‐
ces in gene expression between these populations,  it  has been possible to identify
factors, which critically determine the survival of motoneurons and the neuromuscu‐
lar function in the pathologic context of ALS. Furthermore, we discuss the contribu‐
tion of non-cell autonomous processes, involving glial cells and the skeletal muscle, in
the neurodegenerative process. Exploring the cause of neurodegeneration from the
angle of the selective neuronal vulnerability has recently led to the identification of
novel targets, which open opportunities for therapeutic intervention against ALS.
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1. Introduction
Amyotrophic lateral sclerosis (ALS) primarily affects the motor system, which controls both
voluntary and involuntary movements, including vital functions such as breathing, through
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the activity of various types of motoneurons (MNs). Paralysis and death of the patients, which
typically occurs within a few years after disease onset, is caused by the progressive dysfunc‐
tion and degeneration of MNs in the cortex, brainstem and spinal cord. Remarkably, it has
been established that the different types of MNs are not equally affected by ALS. This leads
to contrasted effects on the motor system. For instance, with disease progression, patients lose
their ability to speak, swallow and move, but they keep normal visual, sexual and bladder
functions. Indeed, MNs located in the oculomotor and Onuf’s nuclei are remarkably resist‐
ant to the disease [1]. In contrast, spinal MNs controlling voluntary movements, hypoglossal
MNs important for swallowing and breathing, as well as the upper MNs, are typically among
the first neurons to degenerate.
Upper MNs, also known as Betz cells or corticospinal MNs (CSMNs), are glutamatergic
neurons located in the primary motor cortex and which activate lower MNs in the brainstem
and spinal cord. Upon activation, the lower MNs induce muscle contraction via the release of
the acetylcholine neurotransmitter in the neuromuscular junction (NMJ), a specialized synapse
contacting the skeletal muscle fibers. The ensemble formed by lower MNs and the innervated
muscle fiber is called the motor unit.
Spinal MNs are subdivided into α, β and γ MNs, depending on the type of muscle fibers
they innervate (reviewed by [2]). In ALS, it is mainly α-MNs that degenerate. However, it is
recognized that within the class of α-MNs, there is also a predictable variation in neuronal
vulnerability to disease [3, 4]. It is therefore important to distinguish the following sub‐
types of α-MNs, defined by the contractile properties of the motor unit they are part of: the
fast twitch fatigable (FF) MNs, the fast twitch fatigue-resistant (FR) MNs and the slow twitch
fatigue-resistant (S) MNs [5]. This classification is also based on other characteristics, such as
the size of the neuronal soma (FF MNs have larger cell bodies than S MNs), axonal conduc‐
tion velocity (FF MNs are faster than S MNs), dendrite branching (FF MNs display a more
complex dendritic tree than S MNs) [6], as well as the electrical properties of each of these
MN subtypes [7].
The selective vulnerability observed between the different types of MNs provides a remarkable
opportunity to explore the factors that specifically contribute to neurodegeneration. Until now,
this approach has been mainly based on animal models overexpressing mutated forms of the
superoxide dismutase 1 (SOD1) protein. Indeed, in more than 20% of the familial ALS cases
(fALS), the SOD1 protein carries point mutations associated with autosomal dominant
inheritance. Rodent models overexpressing mutated forms of SOD1 (mSOD1), often under the
control of the human SOD1 promoter, faithfully replicate major clinical aspects of ALS [8–10].
Furthermore, MN subpopulations display a selective vulnerability pattern very similar to the
one observed in humans [8]. These animal models are therefore instrumental to investigate
the molecular and cellular mechanisms underlying the disease process. In this review, we will
discuss how the research on ALS has identified novel therapeutic targets by comparing
different MN subtypes in SOD1 models of fALS.
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2. Comparing different populations of MNs
A careful analysis of disease progression in the high-copy SOD1G93A mouse models of ALS
has allowed defining different stages of the disease. The first behavioral alterations occur as
early as postnatal day 10 (P10), with a delay in the righting reflex and an increase in the
number of mistakes observed in forelimb placement [11]. Around P50, subtle changes in
mouse gait and muscle strength can be observed [12, 13] and by P80, clear impairments in
the motor performance can be detected [14]. At 3 months of age, the animals reach disease
onset, which is characterized by fine tremors, muscle atrophy and loss of body mass [15]. A
severe paralysis of the hindlimbs is observed on average at P120 [16]. Soon after P135, the
ALS mice become unable to right themselves when placed on their side, which is consid‐
ered as the humane disease endpoint [15]. This highly reproducible course of the disease has
been used to identify the corresponding neurodegenerative events in the mouse spinal cord.
Thorough analysis has revealed a precise sequence in the loss of the different types of MNs,
allowing for longitudinal studies to determine molecular and cellular correlates in the disease
process.
2.1. Progression of the SOD1 pathology in mouse models of fALS
2.1.1. Spinal MNs
Spinal MNs are responsible for the control of voluntary movements. For instance, MNs located
in the lumbar part of the spinal cord control the movement of the hindlimbs (Figure 1). These
MNs innervate muscles, such as the gastrocnemius, which are composed of different types of
muscle fibers. The type and the contractile properties of each muscle fiber are defined by the
type of the innervating MN [5] (Figure 2). During the course of the disease observed in the
high-copy SOD1G93A mice, the innervation of the gastrocnemius muscle undergoes dramatic
changes that can be recorded by electromyography.
A significant decline of the compound muscle action potential (CMAP) is observed around
P50 [17, 18], followed by a second decline seen around P100 [18, 19]. In line with the CMAP
data, histological analysis has revealed an abrupt loss of muscle innervation at the age of
approximately 50 days, corresponding to lower occupation of the NMJ in the fast twitch muscle
[3, 14]. Therefore, SOD1 pathology leads first to a loss of the innervation of the type IIb muscle
fibers by the FF MNs (Figure 2B). The second wave of denervation, which occurs at the late
presymptomatic stage of the disease, is defined by the pruning of the FR axons innervating
the type IIa muscle fibers [4] (Figure 2C). In contrast, the type I muscle fibers remain innervated
by the S MNs almost until end stage [18]. Moreover, FR and S MNs have been shown to have
a higher capacity for axonal sprouting compared to the FF MNs [3]. They may form new
synapses on the denervated end plates [20] (Figure 2B, C). Although the loss of NMJs is
typically observed early during the course of the pathology induced by mSOD1, the degen‐
eration of MN cell bodies in the ventral horn starts at P100 and rapidly progresses, in line with
the “dying back” process described by [14].
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Overall, these studies highlight a predictable course of degeneration in the SOD1 mouse model,
with evident differences in the vulnerability of the different subtypes of spinal MN. Whereas
FF MNs are more sensitive to the pathology than FR MNs, the S MNs appear remarkably
resistant to the disease. Saxena et al. identified these subtypes of MNs using a retrograde tracer
locally injected either in the lateral compartment of the gastrocnemius muscle, mainly inner‐
vated by FF MNs [3], or in the soleus muscle innervated by FR and S MNs [13]. The labeled
MNs were collected by laser microdissection and their transcriptome analyzed using Affy‐
metrix microarrays. This advanced approach has revealed molecular mechanisms that were
undetectable when analyzing the whole ventral spinal cord. In Section 3, we will discuss our
current understanding of the mechanisms underlying the observed discrepancies in MN
vulnerability.
Figure 1. Transversal comparison of the vulnerability of different populations of motoneurons. Corticospinal, hypo‐
glossal and spinal motoneurons (MNs), as well as neurons located in the trigeminal nucleus, progressively degenerate
during the course of ALS. In contrast, the oculomotor neurons of the third cranial nerve, located in the brainstem, and
which control eye movements, are resistant to disease. Motoneurons located in the Onuf’s nucleus in the sacral region
of the spinal cord, and which are responsible for the sexual and bladder functions, are also resistant to ALS.
Update on Amyotrophic Lateral Sclerosis168
Figure 2. Longitudinal comparison of lumbar motoneurons during progression of the SOD1 pathology. (A) Organiza‐
tion of the motor units in the lumbar spinal cord. (B) The fast fatigable motoneurons (FF) are the first ones to degener‐
ate in the SOD1 ALS mouse model. This degenerative event corresponds to the early denervation of the type IIb
muscle fibers, before the onset of symptoms. (C) A second wave of denervation is observed when the fatigue-resistant
motoneurons (FR) degenerate, mainly affecting the innervation of the type IIa muscle fibers and further progressing
after symptom onset. Note that the axons of the resistant FR and S motoneurons can sprout and reinnervate the vacant
neuromuscular junctions. The slow (S) motoneurons are resistant almost until disease end stage. (D) FF motoneurons
are characterized by early ER stress and high amount of misfolded SOD1, and they abundantly express MMP-9 and
the Na+/K+ ATPase-α3 pump. Disease-resistant S motoneurons are characterized by the expression of the ER chaperone
SIL1.
2.1.2. Corticospinal MNs
The CSMNs localized in the layer V of the motor cortex are responsible for the initiation of the
voluntary movement. These glutamatergic neurons collect, integrate, translate and transmit
signals to lower MNs located in the spinal cord (Figure 1). CSMNs degenerate and die in ALS
patients [21, 22]. There is also experimental evidence for the degeneration of CSMNs in the
SOD1 animal models of fALS [23]. However, their role in the SOD1G93A mouse model has been
long overlooked; as without specific markers, it was difficult to discriminate these cells from
other types of pyramidal neurons located in the layer V of the cortex. Retrograde tracers, as
well as some adeno-associated viral (AAV) vectors able to retrogradely transduce neurons
from their axonal projections, have proved their utility to study CSMNs [24]. Using retrograde
tracers, a degeneration of the corticospinal tract and a loss of CSMNs were observed at end
stage in SOD1G93A fALS mice [25]. By combining retrograde tracers together with morpholog‐
ical and molecular approaches, Ozdinler et al. could demonstrate that CSMNs degenerate as
soon as P30 in SOD1G93A fALS mice [26]. Indeed, they observed a decrease in the size of CSMN
somas, which were also found positive for markers of apoptosis. Already at P5, 2% of the
neurons positive for CTIP2 (a transcription factor specific for CSMNs in layer V) display
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pyknosis. However, the most dramatic degeneration of the corticospinal tract is observed
between P60 and P120, accompanied by astrogliosis and microgliosis in the neocortex at a later
stage of the disease. Later, CSMNs could be easily identified in a transgenic mouse line
expressing eGFP under the control of the ubiquitin carboxy-terminal hydrolase L1 (UCHL1)
promoter [27]. By crossing these mice with SOD1G93A mice, it was possible to analyze eGFP-
expressing upper MNs in the context of ALS [28]. In the near future, this mouse model could
be used for transcriptomic and proteomic analyses, which may provide further insight into
the molecular mechanisms occurring in CSMNs during the course of ALS. A recent study by
Gautam et al. [29] used the UCHL1-eGFP mice crossed with an Alsin KO mouse line to study
in CSMNs the impact of ALS2, a gene involved in a small percentage of fALS cases. Intrigu‐
ingly, Uchl1 null mice completely lacking UCHL1 activity show motor deficits, with a
progressive and dramatic loss of CSMNs [30]. Although Uchl1 has not been linked to ALS yet,
it will be interesting to further address the role of this gene in ALS. Moreover, analyzing the
spinal MNs in this mouse model could shed some light on the impact of the CSMN degener‐
ation on lower MNs.
However, it remains unclear what is the exact contribution of CSMN degeneration to the
deficits observed in animal models of the SOD1 fALS pathology. Importantly, the silencing of
mSOD1 in the cortex of SOD1G93A rats can delay disease onset, and extends animal survival
[31]. Even more, the treatment has neuroprotective effects on spinal MNs, preventing dener‐
vation of the NMJs. These data highlight the role of CSMNs in ALS, which may have been
underestimated. Further longitudinal studies will be needed to explore the molecular mech‐
anisms leading to CSMN degeneration in ALS and uncover potential therapeutic targets.
2.2. Transversal studies to compare motor nuclei
2.2.1. Onuf/oculomotor versus spinal/hypoglossal MNs
Pools of MNs located in the Onuf’s and oculomotor nuclei are considered resistant to the
disease. MNs located in the oculomotor nucleus are responsible for most of the eye movements.
This function remains mostly intact in ALS patients, although slight defects can be detected
toward end stage, in patients maintained with respiratory assist devices (reviewed by [32]).
Similarly, the disease does not affect the survival of MNs in the Onuf’s nucleus, which controls
sexual and bladder functions [1]. In this nucleus, only few degenerating hallmarks have been
observed, such as pyknotic nuclei or Bunina bodies [1]. The apparent resistance of the
oculomotor and Onuf’s nuclei contrasts with the progressive degeneration of spinal, hypo‐
glossal and trigeminal MNs responsible for the locomotion, swallowing and the control of the
jaw musculature, respectively [33, 34] (Figure 1).
Several research groups have taken advantage of the differential vulnerability between these
motor nuclei to investigate the underlying molecular mechanisms [35–37]. These studies used
techniques including the local injection of retrograde tracers, laser microdissection of cell
subtypes and high-throughput analysis of gene expression.
Using microarrays, Kaplan et al. [38] determined in wild-type (WT) mice the gene expression
profiles of the oculomotor and Onuf’s nuclei, as compared to the vulnerable spinal MNs. A set
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of genes, including the matrix metalloproteinase 9 (MMP-9) and Hydroxysteroid (17-Beta)
Dehydrogenase 2 (Hsd17b2), was found to be expressed at higher levels in the vulnerable
spinal MNs, as compared to the resistant ones. Conversely, semaphorine3e (Sema3e) showed
higher expression in the resistant MNs.
Another study compared oculomotor MNs, hypoglossal MNs and cervical spinal MNs in WT
rats, and found that the pattern of expression of a set of genes was specific for each of these
MN subpopulations [39]. Based on those results, protein levels were determined for six key
genes, comparing their expression in WT and SOD1G93A mice [40]. This study identified a
protein expression signature specific to the disease-resistant oculomotor MNs, as compared
to hypoglossal and spinal MNs. The GABAA receptor α1, the guanylate cyclase soluble subunit
α3 and the parvalbumin protein were highly expressed in the resistant MNs. Conversely,
vulnerable MNs displayed higher protein levels of dynein, peripherin and GABAA receptor
α2. These data suggest that differences in excitability, calcium handling and retrograde
transport machinery may underlie the observed vulnerability pattern. Remarkably, these
differences in protein expression were found to be conserved in the mouse and human species
[40].
In an electrophysiological study using the high-copy SOD1G93A mouse model, Venugopal et
al. [41] compared the excitability of the vulnerable trigeminal MNs (TMNs) and the resistant
oculomotor MNs ex vivo, at P8–12. Using a system based on the membrane properties of MNs,
and a statistical clustering approach to predict the type of motor unit—i.e. FF, FR or S—, they
could determine early perturbations of the firing threshold in the SOD1G93A MNs. TMNs with
low excitability had a decreased threshold, whereas the subpopulation of highly excitable
TMNs had an increased firing threshold. Remarkably, no such electrophysiological effects of
the SOD1G93A pathology were observed in the oculomotor MNs.
Overall, despite the fact that these different pools of MNs have similar physiological roles,
they display clear differences in their vulnerability to the ALS pathology. Transversal studies
have already identified some of the mechanisms that may confer MN susceptibility to the
disease.
3. Possible mechanisms implicated in selective motoneuron vulnerability
Here, we will summarize both intrinsic and extrinsic mechanisms, which may underlie the
differences between subtypes of MNs in their ability to cope with the ALS pathology.
3.1. Intrinsic mechanisms
3.1.1. SOD1 misfolding and ER chaperones
One of the leading hypotheses for the cause of ALS is the gain of toxic properties resulting
from the accumulation of misfolded proteins including SOD1. In normal conditions, the
cytosolic SOD1 protein undergoes several maturation steps to acquire proper structure and
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function. These steps include the binding of copper and zinc and the formation of an intra‐
molecular disulfide bond, to form an enzymatically active and stable homodimer [42]. When
the SOD1 protein carries pathogenic mutations, it has an increased propensity to misfold
(misfSOD1), leading to aggregation and accumulation in organelles such as the Endoplasmic
Reticulum (ER) and the mitochondria [43]. Aggregation of SOD1 has been observed in patients
with fALS [44, 45] and has also been reported in sporadic cases of ALS (sALS) [45, 46]. Using
antibodies that specifically recognize misfSOD1 [47], Saxena et al. [7] found an accumulation
of misfSOD1 in the FF MNs, as soon as P7 in the high-copy SOD1G93A mouse model (Fig‐
ure 2D). In order to determine the changes in gene expression concomitant with the accumu‐
lation of misfSOD1, they performed a longitudinal study to compare the transcriptional profile
of FF and FR/S MNs in the lumbar spinal cord [13]. Remarkably, the FF MNs are subjected to
ER stress already at 3 weeks of age, which is 20 days before the initial denervation of the
corresponding muscle in this animal model. It is only later, at about P50, that the more resistant
FR MNs display similar gene expression changes indicative of ER stress. No such response is
observed in the S MN almost until end stage, which is consistent with their apparent resistance
to disease.
In-depth analysis showed that two ER chaperones have an important role in MN vulnerability:
Calreticulin (CRT) and SIL1 (Figure 2D). CRT is a protein that binds Ca2+ ions. Interestingly
CRT has been shown to be two-fold decreased in the FF MNs compared to S MNs, as soon as
P38 [48]. In vitro, the authors showed that the lower CRT expression contributes to ER stress
and calcium homeostasis disturbance, eventually leading to MN death. The role of CRT was
confirmed in vivo, by crossing SOD1G93A mice with heterozygous CRT+/− mice [49]. The lower
level of CRT expression accelerates the progression of the SOD1 pathology, prompting the
initial loss of NMJ and leading to early muscle weakness. However, low CRT expression did
affect neither the long-term survival of MNs nor animal survival, indicating that CRT is mainly
implicated in the most vulnerable FF MNs during the early phase of the disease.
In an effort to find factors regulating the ER stress response in specific pools of MNs, Filézac
de l’Etang et al. [50] analyzed in WT mice by real-time PCR the expression of a series of genes
involved in protein folding, protein quality control and stress sensing, and compared the level
of gene expression in FF and FR/S MNs. SIL1 was found to be six-times more expressed in S
MNs than in FF MNs. SIL1 is a cochaperone protein, which increases the availability of the ER
chaperone BiP by catalyzing the release of ADP from the ADP-BiP complex, and thereby
facilitates the dissociation of BiP from its substrates. In the spinal cord of Sil1−/+ mice, the ER
unfolded protein response (UPR) is restricted to the FF MNs, whereas in Sil1 null mice, ER
stress signaling is induced in all MNs. In the SOD1G93A ALS mice, SIL1 expression is reduced
in FF MNs, compared to S MNs. However, when SIL1 is overexpressed in MNs using an AAV6
vector, UPR and ER stress signaling are reduced. Moreover, lifespan is prolonged by 84 days
in the low-copy SOD1G93A mouse model, and 37 days in the high-copy SOD1G93A mouse model.
Conversely, reduced SIL1 activity accelerates the ALS pathology in Sil1−/+ SOD1G93A mice, and
reduces the animal lifespan. Finally, both in vitro and in vivo experiments show that SIL1,
coupled with BiP activity, controls ER homeostasis.
Update on Amyotrophic Lateral Sclerosis172
3.1.2. MMP-9
By comparing cranial and spinal MNs with the disease-resistant oculomotor and Onuf’s nuclei
in WT mice, the MMP-9 protein was found to be expressed only in the vulnerable MNs [38].
MMPs are zinc-dependent endopeptidases able to degrade extracellular matrix and basement
membrane components. Although the role of MMP-9 in the context of ALS is still poorly
understood, it might be involved in the disruption of the neuronal extracellular matrix
interaction (reviewed by [51]). MMPs have also been shown to promote the inflammatory
process [52]. Kaplan et al. [38] found that MMP-9 is highly expressed in the FF MNs, in contrast
to the S MNs, which have undetectable MMP-9 levels (Figure 2D). Crossing SOD1G93A mice
with MMP-9 null mice [53] has significant effects on the disease process [38]. The denervation
of the fast twitch tibialis anterior muscle is delayed by more than 80 days, and the mouse survival
increased by 25%. Conversely, AAV6-mediated overexpression of MMP-9 in the FF MNs
accelerates the denervation of the tibialis anterior in SOD1G93A mice. However, MMP-9 overex‐
pression in oculomotor neurons does not induce extraocular muscle denervation, suggesting
that other factors may contribute to the resistance to disease in this population of MNs.
Although no mutations in MMP-9 gene have been linked to ALS yet, He et al. [54] found an
association between the C(-1562)T polymorphism in the MMP-9 gene, and risk to develop
Parkinson’s disease and sALS.
3.1.3. Neuronal excitability
FF and S MNs also differ in their excitability profile. Because of their small soma size, the S
MNs have high input resistance, and therefore need less synaptic activation to initiate an action
potential. As compared to MNs with a larger soma size, the firing threshold is reached earlier
in S MNs, followed by the FR and finally the FF MNs [55]. S MNs are therefore considered to
be highly excitable, whereas FF MNs are poorly excitable. S MNs innervate slow twitch muscle
fibers, which are typically part of the postural muscles, whereas the poorly excitable neurons
control fast twitch fibers, highly present in phasic muscles, and which are used when strength
or rapid response is needed. A recent study by Saxena et al. [7] explored how neuronal
excitability might contribute to the vulnerability profile in each of these MN populations. They
were able to genetically modulate MN excitability in vivo using a floxed pharmacologically
selective actuator module (PSAM), coupled either to the 5HT3-receptor to induce neuronal
depolarization, or to the glycine-receptor to induce neuronal hyperpolarization. By activating
these channels with a specific ligand, they could show that enhancing neuronal excitability
decreases accumulation of misfSOD1 and BiP in MNs, which reduces ALS pathology [7].
Conversely, the reduction of MN excitability enhanced accumulation of misfSOD1 and BiP,
accelerating disease progression.
Recently, a study further explored the link between misfSOD1 accumulation and MN excita‐
bility. Ruegsegger et al. [56] found that misfSOD1 binds the Na+/K+ATPase-α3 pump, impairing
its ATPase activity. More specifically, misfSOD1 targets a 10 amino acid stretch, which is
present in Na+/K+ATPase-α3, and not in the closely related Na+/K+ATPase-α1 isozyme.
Remarkably, Na+/K+ATPase-α3 is the main pump expressed in the vulnerable FF MNs. In
contrast, FR MNs have similar expression of both Na+/K+ATPase-α1 and α3, whereas S MNs
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express almost exclusively Na+/K+ATPase-α1. Therefore, there could be a link between MN
vulnerability and the expression of Na+/K+ATPase-α3, which may lead to ion imbalance when
exposed to the deleterious effects of misfSOD1.
Le Masson et al. [57] used a computational model to demonstrate the dramatic effects that ion
imbalance could have in MNs. The low excitable FF MNs have a high-energy demand to trigger
action potentials, increasing their need for ATP. Ion pump deficiency caused by misfSOD1 will
then consequently increase intracellular cation levels, leading to a constant MN depolarization.
The induced burden on the mitochondrial function may affect ATP production, leading to a
deficit in ATP used to restore ion homeostasis. Overall, the instability is increased, spreading
ion imbalance within the MNs. Overall, these studies highlight the role of neuronal activity in
each subpopulation of MNs exposed to the ALS pathology. These findings can be exploited to
pinpoint key targets present in some neuronal subtypes to develop novel therapies.
3.2. Extrinsic mechanisms
3.2.1. CNS compartment
Over the 20 past years, it has been long debated whether ALS should be considered as a cell
autonomous disease, mainly taking place in the MNs. It is now well established that astrocytes,
oligodendrocytes and microglia also play a role in the pathology (reviewed by [58, 59]). Animal
models of the SOD1 pathology have been intensively used to address this question. First, when
the mSOD1 was selectively expressed in neurons using a panneuronal promoter, an ALS
phenotype was observed only after 400 days [60]. It was next observed that expression of
mSOD1 with a MN-specific promoter does not produce any ALS phenotype [61, 62]. Similarly,
expression of mSOD1 only in astrocytes or microglia failed to produce any pathology [63, 64].
Next, several studies used fALS mice carrying a floxed mSOD1 transgene to selectively excise
the transgene by expressing the Cre recombinase only in a given cell types. Using this
approach, they could demonstrate that mSOD1 expression in MNs determines the time of
disease onset. Expression of mSOD1 in either astrocytes or oligodendrocytes affects both
disease onset and progression [65, 66], whereas the pathogenic contribution of mSOD1 in
microglial cells is mainly observed during disease progression [67]. Similar effects have been
observed with a different approach, using an AAV-based system to selectively express an
artificial microRNA to target mSOD1 either in MNs or in astrocytes [68].
The majority of the vulnerable MNs are already degenerating before the clinical onset of the
disease (Figure 2). When the resistant pool of MNs undergoes degenerative changes, they are
typically exposed to a local environment containing reactive glial cells. Indeed, astrocytes and
microglia become activated mainly in the late phase of the pathology. Several studies have
shown their implication in the progression of the disease after the onset of the symptoms, most
likely via their pathogenic interaction with the remaining MNs.
These findings point out the importance to investigate the role of broad range of cell types in
the ALS pathology. Sun et al. [69] have recently addressed the temporal sequence of gene
expression changes occurring in glial cells in the SOD1G37R mice. They applied the translating
ribosome affinity purification (TRAP) technique [70], coupled with high-throughput RNA
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sequencing, to investigate the gene expression changes in MNs, astrocytes and oligodendro‐
cytes. Just before disease onset, they observed the most prominent gene expression changes
in MNs, mainly affecting the ER stress pathways. Later, astrocytes show changes in the
expression of genes mostly involved in inflammation and metabolism. In oligodendrocytes,
gene expression is most significantly changed at an early symptomatic stage. The observed
dysregulation affects genes implicated in the myelination and lipid signaling pathways. This
result somewhat contrasts with the delay in disease onset, which has been previously observed
following the selective excision of mSOD1 in oligodendrocytes [65].
Oligodendrocytes are known to support the metabolic activity and the myelination of axons
in the CNS (reviewed by [71]). Degenerating oligodendrocytes have been observed in ALS
mice and patient tissues. Moreover, the pool of oligodendrocyte progenitors, identified by the
expression of NG2, fails to properly differentiate, and they generate oligodendrocytes lacking
expression of the myelin basic protein (MBP) and monocarboxylate transporter 1 (MCT1) [65,
72]. The loss of MCT1 may contribute to MN vulnerability, as this transporter is normally
required for the supply of lactate, which is an important energy substrate for axonal support
[73]. Remarkably, MCT4—another lactate transporter— is preferentially expressed in astro‐
cytes and is reduced in ALS [74].
Although the role of astrocytes in ALS has raised a lot of interest, the mechanisms underlying
astrocyte-mediated toxicity toward MNs are still incompletely resolved. The interaction
between astrocytes and MNs has been mainly explored in vitro, using coculture systems.
Recently, Meyer et al. [75] were able to differentiate “induced astrocytes” (i-astrocytes) from
neuronal progenitor cells derived from the fibroblasts of ALS patients. In cocultures of MNs
and i-astrocytes derived from SOD1 ALS, C9ORF72 ALS and sALS patients, the astrocytes are
toxic to MNs, similarly to cocultures using astrocytes derived from the ALS spinal cord [9,
76]. This study suggests that astrocytes may convey toxic effects toward MNs, regardless of
their tissue of origin. One of the first mechanisms proposed for astrocyte toxicity is the potential
excitotoxicity caused by glutamate mishandling (reviewed by [77]). In ALS patients, there is
reduced expression of the excitatory amino acid transporter 2 (EAAT2), which is the main
glutamate transporter in astrocytes [78–80]. Inefficient removal of glutamate from the synaptic
cleft may lead to MN hyperactivation and to a massive entry of calcium. Calcium influx into
MNs can overload the storage capability of the ER and mitochondria, particularly in MNs
where calcium storage could be already impaired [57, 81]. Several studies have highlighted
the secretion of toxic factors by glial cells expressing mSOD1. Indeed, in vitro experiments have
shown that activated astrocytes and microglia expressing mSOD1 secrete toxic factors such as
FasL, nitric oxide (NO) and the IFN-γ cytokine. These factors can induce the death of MNs
expressing mSOD1 (reviewed by [82]). In particular, the coculture with mSOD1 astrocytes
leads to the selective death of MNs mediated through the LIGHT-lymphotoxin-β receptor
death pathway [83].
Therefore, although glial cells are essential to support the function and metabolism of MNs in
the healthy CNS, they are likely to play an active role in the disease process. Astrocytes,
oligodendrocytes and microglial cells carrying ALS-causing mutations appear to malfunction,
leading to the selective death of MNs.
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The release of misfSOD1 is another major component, which may contribute to MN degener‐
ation via extrinsic mechanisms. As mentioned before, misfSOD1 plays an important role in the
degeneration of MNs and its toxicity has been implicated in many cellular dysfunctions
(review by [58]). Most importantly, recent evidence suggests a role of misfSOD1 also in some
sALS cases that are not related to SOD1 mutations. It has been demonstrated that misfSOD1
can convert WT SOD1 [84, 85] leading to the formation of fibrils and aggregates in vitro [86].
High expression of WT SOD1 can lead to an ALS-like phenotype in mice [87]. A prion-like
mechanism of propagation of misfSOD1 from cell to cell has been highlighted in the past few
years (reviewed by [88]). In ALS, exogenous mSOD1 protein [85], as well as the WT SOD1
protein [89], has been shown to penetrate the cell membrane of neuron-like cells by mecha‐
nisms related to macropinocytosis. Cell-to-cell transfer of misfSOD1 may also be mediated by
the ER chaperone chromogranin or through exosomes [26, 90]. Importantly, disease onset
occurs earlier in mSOD1 mice crossed with mice overexpressing chromogranin A, demon‐
strating that this mechanism may have an important role in vivo [91]. Basso et al. [90] highlight
a potential role for astrocytes in mSOD1 propagation. Indeed, they compared in vitro the
proteome and secretome of WT SOD1 and SOD1G93A astrocytes. Interestingly, these latter
produced less protein than the WT SOD1 astrocytes. However, although fewer proteins are
secreted by astrocytes expressing mSOD1, the amount of proteins shed via exosomes is
increased. Furthermore, exosomes derived from astrocytes can transfer mSOD1 to MNs and
induce cell death. It is proposed that astrocytes may secrete mSOD1 to limit the intracellular
deposition of SOD1 aggregates. In turn, the released mSOD1 may exert toxic effects on
neighboring cells. For example, exogenous forms of mSOD1 can be toxic to MNs in vitro via
microglial activation [92].
Although experimental evidence for the propagation of misfSOD1 is still lacking in vivo, these
results suggest that several cell types, including neurons, astrocytes and microglia, may
contribute to the transfer of the protein and lead to toxic effects throughout the CNS. This
pathogenic mechanism may participate in the cascade of events leading to MN degeneration,
while the disease is progressing. With high level of SOD1 protein expression, and low levels
of ER chaperones, MNs may be particularly vulnerable in case of exposure to misfSOD1.
3.2.2. PNS compartment
On top of the CNS components, it is also important to investigate the role of cells that may
control the function of specific subtypes of MNs in the periphery, especially the Schwann cells
and the skeletal muscle.
3.2.2.1. Schwann cells
The Schwann cells are the counterparts of oligodendrocytes in the peripheral nervous system
(PNS), as they are the primary supporting and myelinating cells for the neurons in the PNS.
Surprisingly, the suppression of mSOD1 in Schwann cells accelerates disease progression [93].
The terminal Schwann cells (TSCs) are also of particular interest as they play an important role
in the maintenance, plasticity and regeneration of the NMJs (reviewed by [94]). Semaphorin
3A (Sema3a), a chemorepellent expressed by TSC, is involved in the repulsion of motor axons
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away from the end plate, leading to the denervation of the NMJ [95]. Remarkably, during
reinnervation or toxin-induced paralysis of the gastrocnemius muscle, Sema3a is abundantly
expressed by TSC located at the NMJ of type IIb/x muscle fibers, which are known to have low
sprouting capacity [3, 96]. Even more intriguing is the upregulation of Sema3a in the TSC
covering the motor nerve terminals innervating the type IIb/x muscle fibers in a mouse model
of ALS [97]. Blocking the Sema3a receptor NRP1 was found to delay NMJ denervation in ALS
mice, extending their lifespan [98], thus suggesting that Sema3a could contribute to the early
loss of NMJ in these specific muscle fibers in ALS, and be implicated in their low sprouting
capacity [3]. Moreover, a recent study has highlighted an increase of Sema3a levels in the motor
cortex of ALS patients [99].
3.2.2.2. Muscle
One of the first changes observed in ALS patients and mouse models is the denervation of the
NMJ, often long before the death of MNs. However, the role of the muscle in ALS is still debated
(reviewed by [100]). Dobrowolny et al. [51] showed that overexpression of mSOD1 specifically
in the muscle tissue leads to muscle atrophy and a loss of muscle strength. However, the
shRNA-mediated silencing of mSOD1 in the muscle of SOD1 ALS mice, using either an AAV
vector [101] or a lentiviral vector [102], does not provide any beneficial effect. The absence of
any protective effect was confirmed using mice with Cre expression restricted to the skeletal
muscle to suppress floxed mSOD1 in a tissue-specific manner [102]. Although these studies
indicate that the skeletal muscle is not a primary site for the SOD1 pathology, it may have an
important role in the maintenance of the neuromuscular connections. The neurite outgrowth
inhibitor A (Nogo-A) is upregulated in the skeletal muscle of the mSOD1 mouse model and
in ALS patients and this upregulation seems to occur specifically in the slow twitch muscle
fibers [103]. Moreover, Nogo-A expression correlates with the severity of the clinical symptoms
[104]. Overexpression of Nogo-A in the mouse muscle induces NMJ denervation, whereas
crossing mSOD1 mice with Nogo-A KO mice protects the NMJ [105, 106]. Therapeutic
approaches to block the action of Nogo-A have been proposed. Injection of an anti-Nogo-A
antibody in SOD1G93A mice from the age of 70 days onward protects motor units and increases
muscle strength in 90-day-old mice, although this protective effect seems to be lost at 120 days
[107]. Ozanezumab, a humanized version of the anti-Nogo-A antibody, has been tested in ALS
patients in a phase I clinical trial [108]. Overall, it appears that pathogenic processes taking
place in the skeletal musculature can impact on the neuromuscular function, via mechanisms
that may be specific to motor unit subtypes.
4. Identification and validation of therapeutic targets
Despite years of research and clinical testing, Riluzole remains the only FDA approved drug
for ALS. It is therefore urgent to identify novel targets for therapeutic intervention against MN
degeneration. The study of the different types of MNs highlights the fact that subpopulations
of MNs can survive for long term and function in the context of the disease, which provides
novel molecular targets for neuroprotective treatments.
Selective Vulnerability of Neuronal Subtypes in ALS: A Fertile Ground for the Identification of Therapeutic Targets
http://dx.doi.org/10.5772/63703
177
One possibility is to identify factors that are active in the most vulnerable neurons, and design
approaches to reduce their activity, with the hope to obtain neuroprotective effects in ALS. In
SOD1 mice, MMP-9 has recently been shown to cause deleterious effects in the FF MNs, where
it is preferentially expressed [38]. Edaravone is a free radical scavenger that inhibits MMP-9
upregulation [109]. This compound has been used since many years ago for the treatment of
cerebral infarction or ischemic stroke. Edaravone has demonstrated therapeutic efficiency in
the SOD1G93A mouse model [110] as well as in the SOD1H46R rat model [111], and more recently
in the wobbler mice, which is often considered as a model for sALS [112]. A phase II clinical
trial has shown that Edaravone can slow down the progression of the motor impairments in
ALS patients, although this effect could not be statistically confirmed in a recent phase III trial
[113]. Nevertheless, further analysis of the results has revealed the beneficial effects of the
compound in a subgroup of ALS patients, according to the revised El Escorial diagnostic
criteria, prompting the initiation of a new trial (http://www.alzforum.org/news/conference-
coverage/does-free-radical-scavenger-edavarone-slow-als).(http://www.alzforum.org/news/
conference-coverage/does-free-radical-scavenger-edavarone-slow-als). Of note, Edaravone is
already approved in Japan for the treatment of ALS.
Another possibility is to identify proteins that are expressed only in the disease-resistant MNs.
Here, factors implicated in the control of ER stress may play an important role in MNs
(reviewed by [114]). Possible therapeutic approaches to relieve ER stress have been tested in
the context of the ALS mice. For instance, Salubrinal has been shown to reduce ER stress [115].
In SOD1 mice, Salubrinal administration alleviates disease manifestation and slows down the
progression of the disease [13]. However, Salubrinal as such cannot be used for treating ALS
patients as it has been shown to affect long-term memory in mice [116]. Guanabenz is another
FDA approved antihypertensive drug known to reduce ER stress. Its efficacy in ALS mice is
however still controversial [117, 118]. It is therefore important to unravel targets that may be
more specific to ALS. The discovery that the ER chaperones SIL1 and CRT are centrally
involved in the most resistant populations of MNs has raised attention to these factors as
potential specific targets [49, 50]. In particular, AAV-mediated overexpression of SIL1 in the
MNs of ALS mice dramatically increases innervation of the NMJs and prolongs animal survival
by 25—30%. However, it remains to be determined how to therapeutically target these factors
in ALS patients, perhaps using adapted pharmacological approaches.
As the vulnerability of MNs could be caused by the accumulation of misfSOD1 in these cells,
one potential therapeutic strategy is to prevent SOD1 toxicity by targeting the partially
unfolded intermediates of the SOD1 protein that can later form aggregates. Israelson et al. [43]
recently identified an ATP-independent protein chaperone called multifunctional macrophage
migration inhibitory factor (MIF). This factor prevents the misfolding of SOD1, and decreases
cell death in MNs expressing SOD1G93A in vitro. Moreover, this chaperone is expressed only at
low levels in MNs, which may contribute to their selective vulnerability.
Another approach to prevent SOD1 misfolding is to provide the metal cofactors that are critical
for the proper folding and stability of the functional Cu/Zn SOD1 dimer (reviewed by [119,
120]). CuATSM is a chelator widely used for PET-imaging as it rapidly carries copper across
the blood-brain barrier into the CNS. Preclinical studies in SOD1 mouse models have reported
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beneficial effects of CuATSM, including on animal survival [121, 122]. Recently, Williams et
al. [123] used transgenic SOD1G93A mice coexpressing the Copper-Chaperone-for-SOD (CCS)
protein, which is normally expressed in humans but not in mice. Although these mice do not
live longer than 2 weeks, the treatment with CuATSM delayed onset and slowed down the
progression of the disease, dramatically extending the lifespan of these animals to 18 months
[123]. A phase I clinical trial will be soon initiated to test the effects of CuATSM in ALS patients.
Other strategies directly target SOD1 to prevent its deleterious effects. The use of antibodies
specific for misfSOD1 has been proposed [47, 124, 125]. On the other hand, gene therapy
techniques can be used to reduce the overall level of SOD1 expression. This approach can be
considered as SOD1 null mice are viable and do not show any obvious motor dysfunction
(reviewed by [126]). Viral vectors delivering artificial shRNA or microRNA for RNA interfer‐
ence against SOD1 [68, 127–130], as well as antisense oligonucleotides targeting the SOD1
mRNA [131], are currently being investigated to suppress the expression of this protein. It
remains however debated whether these techniques could be effective in patients other than
those carrying SOD1 mutations, as the role of SOD1 in sALS remains unclear [132]. Neverthe‐
less, some mechanisms contributing to SOD1 toxicity, such as ER stress and UPR, are likely to
be implicated in a broad range of ALS cases, providing opportunities for largely applicable
treatments.
5. Selective neuronal vulnerability in non-SOD1 ALS and other
motoneuron diseases
Most of the studies described in this chapter have used the SOD1 mouse model to explore the
selective vulnerability of MNs in ALS [13]. The pattern on MN vulnerability in ALS patients
is still a matter of speculation. At the late stage of the disease, there is a dramatic degeneration
of the MNs throughout the spinal cord. However, as the access to post-mortem tissue at various
stages of the disease is obviously limited, it has not been possible to precisely determine how
the ALS pathology affects the different subtypes of MNs in patients. Nevertheless, the
preservation of the oculomotor and Onuf’s nuclei in ALS patients has been confirmed by
histological analysis [133].
It is also likely that differences exist between familial and sALS, as well as between the different
genetic forms of ALS. This may also reduce the efficacy of therapies tested in the SOD1 model.
SOD1 mutations are the cause of ALS only in a small fraction of the patients. In addition, the
SOD1 pathology does not appear to be associated with Frontotemporal-Lobar degeneration,
which is linked with other forms of ALS (FTLD-ALS) [134]. Therefore, there is an urgent need
for other models of ALS to develop therapies better adapted to the different forms of the
disease. During the past 10  years, genetic studies have identified ALS-causing mutations in
several genes mainly involved in RNA metabolism, such as FUS, TARDBP and C9ORF72. FUS
and TARDBP represent around 3 and 5% of fALS, respectively, whereas C9ORF72 cases are
more prevalent and cover 30—50% of fALS as well as 5—7% of sALS [134]. Moreover, these
genes have been found mutated in both ALS and FTLD-ALS patients, and TDP-43 positive
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inclusions are observed in non-SOD1 ALS patients [134]. Several research groups have
generated rodents either overexpressing mutated forms of these genes or carrying gene
deletions, with the objective to model the ALS pathology. Overall, the current rodent models
for TDP-43-ALS or FUS-ALS display relatively mild MN degeneration. Axonal degeneration
has been seen in the transgenic TDP-43 rat model, which seems to selectively affect the largest
MNs [135]. This observation suggests that selective vulnerability is also likely to occur in the
TDP-43 pathology.
Recently, more emphasis has been placed on modeling C9ORF72-ALS. Mouse lines generated
with a bacterial artificial chromosome carrying a pathogenic hexanucleotide expansion in the
full human C9ORF72 gene did not develop any behavioral symptoms in two independent
studies [136, 137]. By contrast, using AAV vectors to express the G4C2 repeat expansion in the
mouse CNS led to both histological and behavioral defects similar to the pathology observed
in C9ORF72-ALS/FTLD patients [138]. Although 20% of neuron death was measured in the
cortex, motor cortex and cerebellum of these mice, the number of spinal cord MNs was not
reported. With the continuous development of ALS models, it will hopefully be possible to
more accurately design therapeutic approaches against pathogenic pathways that may be
common to different forms of ALS.
The recent development of mouse and human ES and iPS cells could provide an alternative to
in vivo models. Several hundred lines with various mutations have been generated and are
publicly available. In the context of SOD1, these models have been used to explore the non-
cell autonomous pathogenic mechanisms. Survival of mES- or hES-derived MNs is decreased
when the cells are grown on astrocytes differentiated from SOD1 or sporadic-ALS induced
neural progenitors [76, 132]. MNs derived from patients carrying the C9ORF72 repeats display
typical histopathological features, such as nuclear foci and the non-ATG translation of peptides
encoded by the hexanucleotide repeats [139]. Remarkably, these neurons have an increased
susceptibility to glutamate excitotoxicity. FUS, SOD1 and C9ORF72 ALS-derived MNs show
electrophysiological abnormalities [140]. This technology presents the advantage to model a
larger portion of ALS cases, allowing for comparative gene expression profiling experiments
and testing of therapeutic compounds. However, it remains difficult to study the selective
vulnerability of MN subtypes in such in vitro models, as they fail to replicate the differentiation
into cellular subtypes and the precise architecture of the CNS tissue.
Lately, the transcriptome of the cerebellum and frontal cortex was analyzed post mortem in
samples from C9ORF72-ALS and sALS patients [141]. The results show a prominent dysre‐
gulation of genes involved in the UPR and intracellular protein transport machinery in
C9ORF72-ALS. In sALS, it is the genes involved in cytoskeleton organization and synaptic
transmission, which are most affected. One should keep in mind that these molecular changes
reflect only the late stage of the disease and in the future, it will be important to also access
spinal cord tissue to perform similar transcriptome analysis.
More generally, it is tempting to speculate that the selective MN vulnerability observed in ALS
may also apply to other MN disorders, such as spinal muscular atrophy (SMA) and Charcot-
Marie-Tooth (CMT) diseases. In SMA patients, muscle biopsies show atrophy of the type II
muscle fibers, with a compensatory hypertrophy of the type I fibers [142]. Moreover, the Onuf’s
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nucleus is preserved, even in the most severely affected SMA type I patients. Even though
atrophy is restricted to certain muscles in mouse models of the disease, it does not seem to be
related to muscle fiber type or NMJ size [143]. However, the large size MNs innervating the
proximal forelimb and axial muscles are specifically lost in presymptomatic Δ7 SMN mice
[144]. This last observation could indicate a preferential vulnerability of some MN subtypes,
although this will need to be confirmed with more specific markers to identify the FF or S MNs.
CMT is a heterogeneous group of genetic diseases affecting motor and/or sensory functions.
Several genes have been identified linked to demyelinating CMT (CMT1) or axonal CMT
(CMT2). Among the CMT2 cases, 20% are caused by mutations in the MFN2 gene encoding
mitofusin 2 and are referred as CMT2A [145]. Several observations indicate a pattern of
neurodegeneration, which may be very different from ALS. Biopsies of the tibialis anterior in
CMT1 and CMT2 patients show atrophy of the type IIa muscle fibers and hypertrophy of the
type I fibers [146]. Furthermore, in the late-onset CMT2A patients, the soleus muscle is affected
before, and more severely than other leg muscles, including the gastrocnemius [147]. Few mouse
models of CMT2 have been generated and are currently being studied. CMT2A mice based on
the overexpression of MFN2R94Q develop motor deficits correlating with an overabundance of
small axonal fibers in the sciatic nerve [148]. Further studies will be needed to characterize
how CMT2A affects different subtypes of muscle fibers and MN populations, and leads to the
observed neuromuscular impairments.
6. Conclusions
The identification of ALS-causing mutations in the SOD1 gene in 1993 has raised hopes in the
ALS scientific community [10]. One year later, Gurney et al. [8] generated the well-known
SOD1G93A mouse model, which reproduced most of the ALS features, and opened the way for
exploring the causes of the disease and developing therapies. However, the challenge turned
out to be more difficult than expected. Indeed, more than 20 years later, the identification of
therapeutic targets in the mSOD1 mouse model has failed to bring any effective treatment to
ALS patients.
Nevertheless, the characterization of mouse models overexpressing mutant forms of SOD1 has
dramatically improved our understanding of the cellular processes leading to ALS. In
particular, the very reproducible course of the disease observed in these mice has been
instrumental to study the different stages of the disease, highlighting the fact that not all MNs
are equally affected, and that glial cells are important actors in the pathogenic process.
Recently, several research groups have identified critical factors, which determine MN
vulnerability, providing novel targets for therapeutic intervention. One obvious difficulty in
designing treatments for ALS is that at a given stage of the disease, the various pools of MNs
or glial cells may face different toxic mechanisms, depending on their intrinsic vulnerability.
This may limit the therapeutic efficacy of a single drug.
It remains unknown whether the observed MN vulnerability pattern is specific to mSOD1, and
if the identified molecular mechanisms can be applied to other forms of ALS. To address this
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question, it is critical to further develop animal and cellular models of ALS, based on the genes,
which have recently been linked to the disease. By comparing these models, it will be possible
to pinpoint common pathogenic pathways, and with the development of more specific
biomarkers, apply therapies when and where they are the most likely to succeed.
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